Signal Genetics, Inc. (NASDAQ:MGEN) reported Q2 2017 earnings this N/A, coming in at ($0.34) per share, beating Wall Street’s estimates of ($0.47) per Share. Revenue for the quarter came in at $0.72 million beating analyst estimates of $0.46 million
Analyst Coverage For Signal Genetics, Inc. (NASDAQ:MGEN)
These are 4 Buy Ratings .
The current consensus rating for Signal Genetics, Inc. (NASDAQ:MGEN) is Buy (Score: 3.00) with a consensus target price of $15.67 , a potential (35.52% upside)Recent Insider Trading for Signal Genetics, Inc. (NASDAQ:MGEN)
- On 6/22/2017 Adam Scott Levy, Insider, bought 200 with an average share price of $7.55 per share and the total transaction amounting to $1,510.00.
- On 3/10/2017 Kyle Lefkoff, Director, sold 5,800 with an average share price of $14.34 per share and the total transaction amounting to $83,172.00.
- On 3/8/2017 Kyle Lefkoff, Director, sold 15,000 with an average share price of $15.40 per share and the total transaction amounting to $231,000.00.
- On 2/28/2017 Kyle Lefkoff, Director, sold 10,258 with an average share price of $13.89 per share and the total transaction amounting to $142,483.62.
- On 2/23/2017 Kyle Lefkoff, Director, sold 5,902 with an average share price of $14.14 per share and the total transaction amounting to $83,454.28.
- On 11/20/2015 Samuel D. Riccitelli, CEO, bought 14,000 with an average share price of $0.79 per share and the total transaction amounting to $11,060.00.
Recent Trading for Signal Genetics, Inc. (NASDAQ:MGEN) Shares of Signal Genetics, Inc. closed the previous trading session at 11.56 up +0.44 3.96% with 46,008 shares trading hands.